|03/29/17||Global Blood Therapeutics to Present at the 16th Annual Needham Healthcare Conference|
|SOUTH SAN FRANCISCO, Calif., March 29, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), today announced that it will present at the 16th Annual Needham Healthcare Conference in New York, NY on Wednesday, April 5 at 12:10 p.m. Eastern Time.
The presentation will be webcast live and available for replay from GBT’s website at www.globalbloodtx.com in the Investors section.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc. is a clinical-stage biopharm... |
|03/13/17||Global Blood Therapeutics Reports Recent Business Progress and Fourth Quarter and Year-End 2016 Financial Results|
|SOUTH SAN FRANCISCO, Calif., March 13, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today reported business progress and financial results for the fourth quarter and year ended December 31, 2016.
"2016 was a year of consistent execution and rapid advancement across both of our GBT440 clinical programs designed to treat diseases where the patient communities are greatly underserved. This was highlighted by coming to agreement with the FDA on the design of our p... |
|03/01/17||Global Blood Therapeutics Announces Participation at Two Upcoming Investor Conferences in March|
|SOUTH SAN FRANCISCO, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), today announced that it will present at the following investor conferences in March:
Cowen and Company 37th Annual Health Care Conference in Boston, MA on Tuesday, March 7, 2017 at 8:40 a.m. Eastern Time (ET); and
The 29th Annual ROTH Conference in Dana Point, CA on Tuesday, March 14, 2017 at 4:30 p.m. Pacific Time (PT).
The presentations will be webcast live and ava... |
|02/27/17||Global Blood Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Option to Purchase Additional Shares|
|SOUTH SAN FRANCISCO, Calif., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat grievous blood-based disorders with significant unmet need, today announced the closing of its previously announced underwritten public offering of 5,867,347 shares of its common stock at a price to the public of $24.50 per share, which includes 765,306 additional shares of ... |